Journal article
Proton pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).
Abstract
493
Background: PPIs are potent inhibitors of gastric acid secretion and can affect the bioavailability of orally administered cancer targeting therapies, such as vascular endothelial growth factor tyrosine-kinase inhibitors (VEGF-TKIs). Smaller preclinical and clinical studies have attempted to assess the interaction between VEGF-TKIs and PPIs in patients with advanced cancers; however, these studies are limited and larger …
Authors
Lalani A-KA; McKay RR; Lin X; Simantov R; Kaymakcalan MD; Choueiri TK
Journal
Journal of Clinical Oncology, Vol. 35, No. 6_suppl, pp. 493–493
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2017
DOI
10.1200/jco.2017.35.6_suppl.493
ISSN
0732-183X